The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index; none of the 13 sources its claims cite is checked for support yet.
A study of polio vaccination in infancy: excretion following challenge with live virus by children given killed or living poliovaccine
Open accessAbstract
Quadruple vaccine containing 75 D antigen units of killed type 1 poliovirus was given to children at ages 2, 3 and 4 months followed by a booster dose at 15 months. The serological response to the primary course was difficult to assess owing to maternal antibody. Antibody titres to the type 1 component after the booster dose were very satisfactory and about 10 times higher than those observed in a similar group of children given attenuated vaccine. Response to the poliovirus types 2 and 3 in the quadruple vaccine was less satisfactory. Graded doses of attenuated poliovirus type 1 were fed to the children 2 months after the primary course and 1 month after the booster dose. Children who had received no poliovaccine and children immunized with attenuated vaccine were included for comparison. Immunization with killed vaccine did not greatly affect the size of the minimal infecting dose of live virus but reduced both the duration of the subsequent infection and the titre of virus in the faeces. The epidemiological significance of these findings is discussed.
Overview
CoChat Summary
TL;DR
In this London infant trial, killed quadruple poliovaccine produced strong type 1 antibody responses after the booster dose, while oral attenuated vaccine produced lower circulating antibody titres but stronger intestinal resistance to challenge. After graded challenge with attenuated type 1 poliovirus, killed vaccine did not greatly change the minimal infecting dose, but it shortened excretion and reduced the amount of virus shed.
Key findings
- After the booster dose of quadruple vaccine, type 1 antibody titres were “very satisfactory” and about 10 times higher than in a similar group given attenuated vaccine; responses to types 2 and 3 were “less satisfactory.”
- Among children challenged with attenuated type 1 poliovirus, a primary course of killed vaccine did not greatly affect the size of the minimal infecting dose, but children who had received attenuated oral vaccine required a much higher dose to initiate infection.
- Of the children assessed for duration of excretion, none of the infected children in group D excreted for more than 14 days, whereas about two-thirds of infected children in group A and one half in group C excreted for more than 18 days.
- For virus shedding 6–15 days after challenge, most children in the unvaccinated control group B excreted more than 10^4 TCD50/g faeces per day, while many children in groups A and C excreted less; the paper reports that killed-vaccine groups had reduced infectivity by 40%, compared with 90% reduction for attenuated poliovaccine.
- The paper states that 126 children excreted poliovirus type 1 after challenge, and that children with higher pre-challenge antibody titres tended to excrete less virus and for shorter periods.
Methods
- Randomized trial of 236 children enrolled at about 2 months of age from two London areas and allocated to four groups: quadruple vaccine at 2, 3, 4 months; triple antigen control; quadruple vaccine with booster at 15 months; or triple antigen plus oral attenuated poliovaccine.
- Children provided monthly faecal specimens before challenge and twice-weekly specimens for 3 weeks after challenge; blood samples were taken at specified ages to measure neutralizing antibodies.
- Challenge used five serial tenfold dilutions of attenuated type 1 poliovirus; infection, duration of excretion, and amount of virus shed were assessed by virus isolation in cell culture and quantitative titration.
Limitations
- The paper itself notes that the serological response of infants to the primary course was “difficult to assess owing to maternal antibody.”
- Many analyses had reduced numbers because children were not bled at the correct time, serum volumes were too small, some children had natural poliovirus infections, or faecal specimens were missing; for challenge outcomes, 26 children were excluded from infection analysis and 13 more from duration analysis.
- Evident from the text: the trial used only type 1 poliovirus for challenge, so it does not directly test intestinal immunity against types 2 or 3.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 0 Not valid · 11 Not checked · 89 Own results and interpretations
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Some children, with no detectable antibody, reacted to one or more of the poliovirus antigens in the booster dose by producing antibodies to a high titre.”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Examination of the individual protocols showed clearly that it was those children with the lowest titres of maternal antibody who made the best response.”
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“some poliovirus antibodies which can be judged by comparing, in Fig. 1, the results for group A second sera with the group B children who had had no poliovaccine.”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The response to any one of the three poliovirus antigens was not related to the response to the other types.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At the age of 2 months (group A, 1st serum) many children had high titres of maternal antibody, particularly to type 2 virus”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
44 more claims
Create a free account to see all 100 claims and to verify the 13 references still open.
- Probably not a substantial claim. 24
- It may state two separate claims as one. 36
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In contrast, intramuscular injection of IPV induces serum antibodies but does not induce secretory IgA at the mucosal surfaces [3] and has a much more limited impact on the resistance of the intestine to infection [5].”
From Systematic Review of Mucosal Immunity Induced by Oral and Inactivated Poliovirus Vaccines against Virus Shedding following Oral Poliovirus Challenge (2012) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“Five studies that quantified poliovirus shedding found a 63%–91% (or an absolute 0.43–1.0 log10) reduction in the mean quantity of poliovirus shed in stool samples collected from IPV vaccinated compared with unvaccinated children [5], [17]–[20] (Table S1).”
From Systematic Review of Mucosal Immunity Induced by Oral and Inactivated Poliovirus Vaccines against Virus Shedding following Oral Poliovirus Challenge (2012) · cites this paper as [5]
Citations
Cites
Serum gamma globulin levels in normal infants.
Orlandini, O., SASS-KORTSAK, A. M., & Jh, E. (1955) · PubMed · Cited by 109
SERUM GAMMA GLOBULIN LEVELS IN NORMAL INFANTS
T., O. O., SASS-KORTSAK, A. M., & Ebbs, J. H. (1955) · PEDIATRICS · doi:10.1542/peds.16.5.575 · Cited by 97
Serological Response of Infants to Poliomyelitis Vaccine
PERKINS, F. T., Yetts, R., & Gaisford, W. (1958) · BMJ · doi:10.1136/bmj.2.5088.68 · Cited by 49
PERKINS, F. T., Yetts, R., & Gaisford, W. (1959) · BMJ · doi:10.1136/bmj.1.5123.680 · Cited by 31
INTERNATIONAL STANDARDS FOR ANTI-POLIOVIRUS SERA TYPES 1, 2 AND 3.
Lyng, J., & Bentzon, M. W. (1963) · PubMed · Cited by 26
British Standard Poliomyelitis Antisera Types 1, 2, and 3
PERKINS, F. T., & Evans, D. G. (1959) · BMJ · doi:10.1136/bmj.1.5137.1549 · Cited by 24
Immunization of Young Babies Against Diphtheria
Butler, N. R., Barr, M., & Glenny, A. T. (1954) · BMJ · doi:10.1136/bmj.1.4860.476 · Cited by 20
Beale, A. J., & Ungar, J. (1962) · The Lancet · doi:10.1016/s0140-6736(62)92592-8 · Cited by 13
Self-citationDane, D. S., Dick, G. W. A., Simpson, D. H., Briggs, E. M., Mcalister, J., Nelson, R., & Field, C. B. (1962) · The Lancet · doi:10.1016/s0140-6736(62)91974-8 · Cited by 13
Vaccination against Poliomyelitis
Dane, D. S. (1964) · Proceedings of the Royal Society of Medicine · doi:10.1177/003591576405700609 · Cited by 8
Research works printed but not linked: 4
- 1965, The excretion of type 1 poliovirus after challenge following primary immunization with quadruple, Salk and Sabin vaccines. A study by the Public Health Laboratory Service, Mon. Bull. Minist. Hlth, 24, 365
- Galbraith N. S. (1964). Proc. Xth Symposium Europ. Ass. Poliomyelitis and Allied Diseases. Warsaw.
- Dane, 1964, The future of inactivated poliomyelitis vaccines, Proc. R. Soc. Med., 57, 462
- Gard S. (1964). Proc. Xth Symposium Europ. Ass. Poliomyelitis and Allied Diseases. Warsaw.
Cited by
Herd Immunity: History, Theory, Practice
Fine, P. E. M. (1993) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a036121 · Cited by 905
Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: Review.
Patriarca, P. A., Wright, P. F., & John, T. J. (1991) · Clinical Infectious Diseases · doi:10.1093/clinids/13.5.926 · Cited by 453
From Emergence to Eradication: The Epidemiology of Poliomyelitis Deconstructed
Nathanson, N., & Kew, O. M. (2010) · American Journal of Epidemiology · doi:10.1093/aje/kwq320 · Cited by 404
“However, it was recognized that OPV might also spread from vaccinees to their unvaccinated close contacts, thereby increasing the level of immunity in the population (62).”
BackgroundFine, P. E. M., & Carneiro, I. A. M. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009924 · Cited by 247
Mucosal Immunity Induced by Enhanced-Potency Inactivated and Oral Polio Vaccines
Onorato, I. M., Modlin, J. F., McBean, A. M., Thoms, M. L., Losonsky, G. A., & Bernier, R. H. (1991) · Journal of Infectious Diseases · doi:10.1093/infdis/163.1.1 · Cited by 246
“tion after OPV challenge compared with unvaccinated controls but to a lesser degree than in OPV recipients [7-9].”
BackgroundMethodResultInfluential
Metadata
- Authors
- Henry, J. L., Jaikaran, E. S., Davies, J. R., Tomlinson, A. J. H., Mason, P. J., Barnes, J. M., & Beale, A. J.
- Venue
- Journal of Hygiene
- Publisher
- Cambridge University Press (CUP)
- Published
- 1966-03
- Volume
- 64
- Issue
- 1
- Pages
- 105-120
- ISSN
- 0022-1724 (ISSN-L)
- PMC
- PMC2134687
- OpenAlex
- W2131812510
- Cited by
- 101
- References
- 14
- Citations by year
- 2025: 2 · 2023: 4 · 2021: 2 · 2019: 3 · 2018: 1 · 2017: 2 · 2016: 2 · 2015: 2 · 2014: 5 · 2013: 8 · 2012: 6
- FWCI
- 3.50
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Hygiene (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- polio vaccination, infant immunization, inactivated poliovirus vaccine, booster vaccination, serological response, maternal antibodies, antibody titers, infection duration
- MeSH terms
- Humans, Infant, Poliomyelitis, Poliovirus Vaccine, Inactivated, Poliovirus Vaccine, Oral, Vaccination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A study of polio vaccination in infancy: excretion following challenge with live virus by children given killed or living poliovaccine. https://app.cochat.ai/papers/10.1017/s0022172400040389
- The paper
- Henry, J. L., Jaikaran, E. S., Davies, J. R., Tomlinson, A. J. H., Mason, P. J., Barnes, J. M., & Beale, A. J. (1966). A study of polio vaccination in infancy: excretion following challenge with live virus by children given killed or living poliovaccine. Journal of Hygiene. https://doi.org/10.1017/s0022172400040389
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.